Another evidence that supports the continued use of RAS inhibitors in end-stage kidney diseases
Authors:
Open Access
- 24 April 2024
- journal article
- editorial
- Published by Springer Nature in Hypertension Research
- Vol. 47 (7) , 1984-1986
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney DiseaseKidney International, 2024
- Association between stopping renin-angiotensin system inhibitors immediately before hemodialysis initiation and subsequent cardiovascular eventsHypertension Research, 2024
- A Personalized Approach to Chronic Kidney Disease and Cardiovascular DiseaseJACC, 2021
- SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 InhibitionCell Metabolism, 2020
- Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration RateJAMA Internal Medicine, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Effect of Angiotensin Receptor Blockers on Cardiovascular Events in Patients Undergoing Hemodialysis: An Open-Label Randomized Controlled TrialAmerican Journal of Kidney Diseases, 2008
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999